LBRX · Lb Pharmaceuticals Inc
$32.31
+1.41 (+4.56%)
At close · Jul 21
Market Cap
$926.54M
Shares
28.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$32.31
Open$31.43
Day$31.04–32.40
52W$13.36–35.35
Avg vol 30d293K
Short int4.6M · 15.9% float · 9.8d
Short vol53%
DataSep 2025–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+7%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
86%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+43%
trailing
YTD return
+45%
this year
Relative strength
+36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $30 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
3 of 76 funds reported for Jun 30 · net +39.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.87% of float · ▲ +5.8% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
+98%
Y/Y
Free cash flow
$-35.3M
Balance sheet
$250.2M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $30 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
3 of 76 funds reported for Jun 30 · net +39.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.87% of float · ▲ +5.8% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $13
Now $32 · 86%
52-wk high $35
vs 200-day avg +35%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LBRX
this stock
Lb Pharmaceuticals Inc
|
$926.54M | +45.1% | — | — | 15.9% |
|
ONC
BeOne Medicines Ltd.
|
$448.86B | +2.2% | +22179.2% | 913.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.95B | +6.0% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.47B | -12.8% | +20.8% | 16.4 | 3.3% |
|
ARGX
Argenx SE
|
$54.72B | +4.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LBRX | +0.9% | +8.2% | +43.4% | -0.5% | +45.2% |
| SPY | -0.5% | +0.5% | +7.6% | +0.2% | +9.7% |
| vs SPY | +1.4% | +7.7% | +35.8% | -0.7% | +35.4% |